CD274 and neoplasm: First, one of the two cohort is a retrospective study in a single tertiary medical center, so some relevant data of immune profiles including immunophenotyping analysis, any grades of immune-related adverse events, cumulative dosage of PD-1/PD-L1 inhibitors, subsequent treatment after immunotherapy failure, tumor mutational burden, and tumor infiltrated lymphocytes were unavailable.